As utilization of comprehensive genomic profiling (CGP) of solid tumors grows, more distributed kit options are expanding access to NGS-based biomarker profiling. Hear from Illumina experts on recent developments and future expansions to the TruSight Oncology portfolio, including our recently FDA-approve TruSight Oncology Comprehensive.
